Heron Therapeutics Ownership | Who Owns Heron Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Heron Therapeutics Ownership Summary


Heron Therapeutics is owned by 25.41% institutional investors, 0.86% insiders, and 73.73% retail investors. Rubric capital management lp is the largest institutional shareholder, holding 17.48% of HRTX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.07% of its assets in Heron Therapeutics shares.

HRTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockHeron Therapeutics25.41%0.86%73.73%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Rubric capital management lp26.71M17.48%$40.87M
Blackrock funding, inc. /de8.59M5.62%$13.14M
Adage capital partners gp8.50M5.56%$13.01M
Blackrock8.33M5.51%$29.14M
Vanguard group8.16M5.34%$12.48M
Velan capital investment management lp6.99M4.57%$10.69M
Tejara capital4.66M3.05%$7.13M
Palisade capital management, lp3.93M2.57%$6.01M
D. e. shaw3.72M2.44%$5.70M
State street3.15M2.06%$4.81M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Velan capital investment management lp6.99M9.22%$10.69M
Tejara capital4.66M4.67%$7.13M
Jw asset management2.29M1.67%$3.51M
Congress park capital2.46M1.36%$3.76M
Orchard capital management1.88M1.12%$2.84M
Cm management700.00K0.96%$1.07M
Stonepine capital management700.00K0.86%$1.07M
Richmond brothers642.34K0.63%$982.78K
Rubric capital management lp26.71M0.52%$40.87M
Clearline capital lp1.81M0.37%$2.77M

Top Buyers

HolderShares% AssetsChange
Point72 asset management3.08M0.01%3.08M
Blackrock8.33M0.00%1.04M
Stonepine capital management700.00K0.86%700.00K
Morgan stanley767.86K0.00%568.86K
Congress park capital2.46M1.36%477.42K

Top Sellers

HolderShares% AssetsChange
Orbimed advisors---6.51M
Qube research---1.15M
Goldman sachs group655.16K0.00%-1.05M
Renaissance1.19M0.00%-819.40K
Nuveen asset management314.27K0.00%-792.42K

New Positions

HolderShares% AssetsChangeValue
Point72 asset management3.08M0.01%3.08M$4.71M
Stonepine capital management700.00K0.86%700.00K$1.07M
Quinn opportunity partners380.00K0.04%380.00K$581.40K
Bridgeway capital management300.00K0.01%300.00K$459.00K
J. goldman & co lp270.10K0.01%270.10K$413.25K

Sold Out

HolderChange
Allspring global investments-1.00
Toronto dominion bank-9.00
Lindbrook capital-16.00
Northwestern mutual wealth management-53.00
Gps wealth strategies group-72.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202490-48.86%38,837,514-68.12%250.40%37-57.95%24-36.84%
Sep 30, 2024175-9.79%121,805,039-6.02%791.08%87-23.01%38-2.56%
Jun 30, 202419417.58%129,609,4628.61%851.36%11359.15%39-17.02%
Mar 31, 20241655.77%119,336,2116.43%791.33%71-4.05%4727.03%
Dec 31, 202315611.43%112,127,927-4.94%770.80%7442.31%37-5.13%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF4.68M3.07%-
Vanguard Total Stock Mkt Idx Inv4.68M3.07%-
iShares Russell 2000 ETF3.10M2.04%43.61K
Biotech Growth Ord2.58M1.70%2.58M
Palisade Small Cap Core Equity2.52M1.65%49.27K
Vanguard Institutional Extnd Mkt Idx Tr2.18M1.43%-
Franklin US Small Cap Growth Equity1.80M1.19%-
Orchard Small Cap Value ESG1.67M1.09%-26.82K
Orchard US Small Cap Value USD Instl 11.67M1.09%-26.82K
Orchard Select Small Cap Value1.67M1.09%-26.82K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 17, 2023Forbes William P EVP, Chief Development OfficerBuy$27.25K
Nov 16, 2023Forbes William P EVP, Chief Development OfficerBuy$46.99K
Nov 16, 2023Collard Craig A Chief Executive OfficerBuy$137.97K
Nov 16, 2023Duarte Ira EVP, Chief Financial OfficerBuy$75.60K
Jul 21, 2023Morgan Adam-Buy$3.41M

Insider Transactions Trends


DateBuySell
2025 Q2--
2025 Q1--
2024 Q4--
2024 Q3--
2024 Q2--

HRTX Ownership FAQ


Who Owns Heron Therapeutics?

Heron Therapeutics shareholders are primarily institutional investors at 25.41%, followed by 0.86% insiders and 73.73% retail investors. The average institutional ownership in Heron Therapeutics's industry, Biotech Stocks , is 68.48%, which Heron Therapeutics falls below.

Who owns the most shares of Heron Therapeutics?

Heron Therapeutics’s largest shareholders are Rubric capital management lp (26.71M shares, 17.48%), Blackrock funding, inc. /de (8.59M shares, 5.62%), and Adage capital partners gp (8.5M shares, 5.56%). Together, they hold 28.66% of Heron Therapeutics’s total shares outstanding.

Does Blackrock own Heron Therapeutics?

Yes, BlackRock owns 5.51% of Heron Therapeutics, totaling 8.33M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 29.14M$. In the last quarter, BlackRock increased its holdings by 1.04M shares, a 14.27% change.

Who is Heron Therapeutics’s biggest shareholder by percentage of total assets invested?

Velan capital investment management lp is Heron Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.22% of its assets in 6.99M Heron Therapeutics shares, valued at 10.69M$.

Who is the top mutual fund holder of Heron Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Heron Therapeutics shares, with 3.07% of its total shares outstanding invested in 4.68M Heron Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools